Your SlideShare is downloading. ×
  • Like
Dr Brendan Shaw - Medicines Australia - Examining the financial stability of the PBS and ensuring reform savings deliver new medicines in Australia as intended
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Dr Brendan Shaw - Medicines Australia - Examining the financial stability of the PBS and ensuring reform savings deliver new medicines in Australia as intended

  • 298 views
Published

Dr Brendan Shaw delivered the presentation at 2014 Future of the PBS Summit. …

Dr Brendan Shaw delivered the presentation at 2014 Future of the PBS Summit.

The 11th annual Future of the PBS Summit marks a wonderful opportunity to review future frameworks and preferred outcomes for pharmacy regulators, pharmaceutical companies and wholesalers, practitioners, educators and consumers.

For more information about the event, please visit: http://www.informa.com.au/futurepbs14

Published in Business , Technology
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
298
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
12
Comments
0
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Future of the PBS Summit 2014 Confirming  the  financial  stability  of  the  PBS     and     Ensuring  reforms  deliver  new  medicines 6 May 2014 Brendan Shaw, Medicines Australia CEO 1
  • 2. Stability – Certainty – Access 1.  “All  over,  bar  the  Budget”:  the  PBS  is  proven   to  be  on  a  sustainable  path     2.  The  debate  should  be  about  access  to  new   medicines  for  all  Australians     2
  • 3. PBS Expenditure 3  $10,040      $10,188      $9,832     2010-­‐11   2011-­‐12   2012-­‐13   PBS  Expenditure  2010/11-­‐2012/13  ($M)   Final  Budget  Outcome   PBS  as  a  share  of  total  Commonwealth  health  funding   Source:  Final  Budget  Outcome,  2013,  p.  97,   hSp://budget.gov.au/2012-­‐13/content/To/download/ 2012-­‐13_FBO_Consolidated.pdf,  accessed  5/5/2014   Source:  PharmaDispatch,  hSp://www.pharmadispatch.com/?pgnc=1.    
  • 4. PBS expenditure in decline 4 Source:  Federal  Budget,  various  years;  Medicines  Partnership  of  Australia,   PBS  Scorecard,  February  2014,   hSp://medicinespartnership.com.au/category/pbs-­‐scorecards/,  accessed   5/5/2014  
  • 5. Pillars of the National Medicines Policy at risk 5
  • 6. Challenge has moved from sustainability to access 6 72%   61%   55%   57%   24%   32%   36%   33%   4%   7%   9%   10%   0%   10%   20%   30%   40%   50%   60%   70%   80%   2010   2011   2012   2013   Annual  recommendaon  rate,  rejecon  rate  and  deferral  rate  for   submissions  for  medicines  that  were  considered  by  the  PBAC  (2010  –   2013)   Recommenda@on  rate   (medicines)*   Rejec@on  rate  (medicines)*   Deferral  rate  (medicines)*   Source:  Michael  Wonder,  2014,  Unpublished  PBAC  data,  Wonder  Drug   Consulng  
  • 7. 7 International access to medicines Source:  WyaS  Health,  Internaonal  Report  on  Access  to  Medicines,  2011-­‐12,   hSp://www.wyaShealth.com/wp-­‐content/uploads/IRAM/iram-­‐2011-­‐2012-­‐English.pdf,  p.  17,  access  5/5/2014.  
  • 8. International access to cancer medicines 8 Source:  Cheema,  P.  2010  “Internaonal   variability  in  the  reimbursement  of  cancer  drugs   by  publically  funded  drug  programs”,  Medical   Oncology,  v.  19,  n.  3,   hSp://www.current-­‐oncology.com/index.php/ oncology/arcle/view/946/924    (accessed   4/10/2013  )  
  • 9. 9 Additional medicines listed for reimbursement in Australia that are not reimbursed in NZ 0 5 10 15 20 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 NumberofMedicineslistedinAustralia Reimbursed in Aus and NZ Medicines that are reimbursed in Aus but not NZ Source:  PBS  (Australia),  PHARMAC  (NZ)  
  • 10. Source:  PBS  (Australia),  PHARMAC  (NZ Delays in NZ medicines Molecule   Indications   Available in Aus Since:   Time b/w PBS Listing and PTAC Rec   Recommendation by PTAC   Time gap from Australian Recommendation   Rosuvastatin   Cholesterol   1/12/2006   8 months   1/08/2007   6 years 5 months   Buprenorphine hydrochloride   Severe pain   1/08/2001   7 years 8 months   1/05/2009   4 years 8 months   Nilotinib   Chronic myeloid leukaemia   1/08/2008   2 years 6 months   1/02/2011   2 years 11 months   Sorafenib   Advanced hepatocellular carcinoma   1/02/2009   2 years 9 months   1/11/2011   2 years 2 months  
  • 11. New Zealand: Our future? 11 •  Roune  delays  of  up  to  6  years  for  new  medicines   •  Supply  chain  risks  leading  to  shortages   •  No  paent  or  doctor  choice   •  No  tailored  care  to  the  paent’s  condion   •  No  transparency  on  whether  and  when  a  medicine  may   appear  
  • 12. Conclusion •  Two  possible  futures  for  the  PBS  face  us  today   •  PBS  is  sustainable  due  to  industry  efforts   •  The  pillar  of  access  is  failing  but  fixable   •  Australians  expect  a  first  class  medicines   system  in  a  first  world  country   12